Professor of Medicine- Director of the Hope Clinic
Emory University School of Medicine
Disclosure: Lilly (Grant/Research Support)Merck (Grant/Research Support)Pfizer (Grant/Research Support)Quidel (Grant/Research Support)Sanofi Pasteur (Grant/Research Support)
Dr. Nadine Rouphael (MD) is a Professor of Medicine in the Infectious Diseases Division, Department of medicine at Emory University in Atlanta, USA. She graduated from Saint Joseph University School of Medicine in Lebanon (2001). She completed her internal medicine residency (2005) and infectious diseases fellowship (2008) at Emory University. She serves as the executive director of the Hope Clinic, the clinical arm of the Emory Vaccine Center and the Emory principal investigator for the NIH funded Vaccine Treatment and Evaluation Unit (VTEU) and the Clinical Core principal investigator for NIH funded Human Immunology Project Consortium (HIPC). She has served as the national chair/co-chair as well as overall PI/site PI of 50 clinical studies and an investigator on more than 150 studies. She has interest in antimicrobial resistance, vaccine clinical trials (pandemic influenza, Zika, Ebola, SARS-CoV2…), vaccine delivery methods (NIH funded phase 1 trial on microneedle influenza vaccine patch where a first in human dissolvable patch was shown to be safe, immunogenic and preferred to the traditional needle and syringe), translational research on innate immunity and systems biology (using vaccines as way to probe the immune system and one of the first to show an association between antibiotic use and decrease immunogenicity), immune aging and correlates of protection. She has published more than 130 peer reviewed publications (New England Journal of Medicine, The Lancet, JAMA, Nature Immunology, Science, Cell…) and has received many awards.
Recently, she led a team that enrolled the most patients in the world for the Adaptative COVID-19 Treatment Trials (ACTT1,2,3 and 4) resulting in licensure of remdesivir (ACCT1) and approval of baricitinib (ACTT2) by the FDA. She was the lead investigator at the Hope Clinic for the Moderna mRNA vaccine for the phase 1 trial and along with Grady and Emory Children Center at Emory University 700 participants were enrolled in the phase 3 trial that showed early efficacy results in November 2020 with the Emory site having one of the highest diversity among US sites. The vaccine has now been given to millions of people around the world. She is currently serving as the international Chair for the Sanofi efficacy trial studying the safety and efficacy of a monovalent and bivalent protein adjuvanted vaccines. She serves as the national Chair for an observational study IMPACC (Immunophenotyping Assessment in a COVID-19 Cohort) that enrolled 1,227 patients across 20 hospitals in the US to better understand the clinical, virologic and immunologic aspects of severe COVID-19. She served as the Emory PI for Lilly monoclonal antibodies being one of 3 sites to ever test the products in humans. She is currently working on second generation vaccines as she serves as the Emory PI for the Moderna variant vaccines (NCT04785144) and Gritstone vaccines (NCT04776317) as well as the Emory network PI for boost and mix and match approach (NCT04889209) and in pregnant women and neonates. She is involved in Controlled Human Challenge studies.
